StockIQ.techEdwards Lifesciences Corporation (EW) Stock Analysis
Free AI-powered analysis and research for Edwards Lifesciences Corporation stock
Sector: Healthcare
EW snapshot
Data as of 4 Nov 2026 close. Updated daily.
Edwards Lifesciences Corporation scores 99/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 99% of its 52-week range, up 18.4% over the past year. Latest reported figures show a profit margin of 15.4%, return on equity of 9.2% and revenue growth of +13.6%.
What is driving the score
- Strong Uptrend: +10
- MACD Bullish: +8
- High P/E (54.8): -10
- Good Profit Margin (15.4%): +5
- Low Debt (0.07 D/E): +8
- Strong Liquidity (4.52 Current Ratio): +8
- Strong Long-term Uptrend: +8
- Healthy Momentum (+18.4% over 1 year): +7
- Near 52-Week High (99%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full EW report
Edwards Lifesciences Corporation (EW) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze EW Now →📰 Latest Update
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Fri, October 30, 2026 at 12:15 PM UTC 4 min read
Edwards Lifesciences (EW) is set to report its Q3 performance, with Wall Street analysts providing estimates for key financial metrics. Investors are keen to assess the company's growth trajectory and market position, particularly in the heart valve and critical care segments. The upcoming earnings report will be crucial for understanding the impact of recent product launches and market dynamics on EW's overall financial health.